BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the colorectal cancer drug market in China will grow from $261 million in 2011 to $404 million in 2016. According to Colorectal Cancer in China, the increased use of targeted therapies will be a key factor driving growth in this market.
Report findings reveal that although two targeted therapies—Merck KGaA’s Erbitux and Roche’s Avastin—have both been approved by the State Food and Drug Administration in China, the high cost of treatment with these agents has limited their use to colorectal cancer patients in the second- or third-line of therapy. However, Decision Resources expects between 2011 and 2016, Chinese oncologists will use Erbitux and Avastin earlier in the treatment algorithm and more frequently.
“The use of Erbitux and Avastin in first-line treatment of metastatic colorectal cancer patients is common in the major markets, and we anticipate that practice will impact prescribing patterns in China,” said Decision Resources Analyst Jing Wu, M.S., M.B.A. “Because of the premium price of these agents, even a slight increase in patient share will drive increased sales and market growth.”
The analysis reveals that expanded reimbursement of drugs treating colorectal cancer, increased patient spending power and an increase in the number of diagnosed and drug-treated patient populations will also contribute to market growth.
“The number of diagnosed incident cases of colorectal cancer in China will increase five percent annually over our ten-year forecast,” said Ms. Wu. “The increase is due mainly to an aging population and an increase in the age-adjusted risk of colorectal cancer due to increased exposure to various risk factors attributable to colorectal cancer.”
The new report features extensive primary research with Chinese oncologists as well as a market outlook by drug and class through 2016 and colorectal cancer epidemiology through 2021.
About Emerging Markets Reports
Decision Resources is the first and only company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians’ practices.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.